Abstract
The rising prevalence of type 2 diabetes mellitus (T2DM) in the US has led to an increased risk of cardiovascular disease (CVD) among affected individuals. GLP-1RA have been used since 2005 to help manage diabetic patients by controlling glucose levels, weight loss, and in further research, reducing cardiovascular disease. This review examines the cardiovascular effects of GLP-1RA highlighting key clinical trials including the LEADER, SUSTAIN, PIONEER 6, REWIND, and AMPLITUDE-O trials looking at liraglutide, semaglutide oral and subcutaneous, dulaglutide, and efpeglenatide. These studies found a significant decrease in major adverse cardiac events (MACE) in the drug groups when compared to placebo. While lifestyle changes remain essential, GLP-1RAs have been proven to decrease cardiovascular risks in T2DM patients.
Included in
Cardiovascular Effects of GLP-1RA in Patients with Type 2 Diabetes
The rising prevalence of type 2 diabetes mellitus (T2DM) in the US has led to an increased risk of cardiovascular disease (CVD) among affected individuals. GLP-1RA have been used since 2005 to help manage diabetic patients by controlling glucose levels, weight loss, and in further research, reducing cardiovascular disease. This review examines the cardiovascular effects of GLP-1RA highlighting key clinical trials including the LEADER, SUSTAIN, PIONEER 6, REWIND, and AMPLITUDE-O trials looking at liraglutide, semaglutide oral and subcutaneous, dulaglutide, and efpeglenatide. These studies found a significant decrease in major adverse cardiac events (MACE) in the drug groups when compared to placebo. While lifestyle changes remain essential, GLP-1RAs have been proven to decrease cardiovascular risks in T2DM patients.